AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20176737
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg GH/m(2) per day
Trial: 20176737
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg GH/m(2) per day
Trial: 15800019
Drug: Standard-dose reteplase
RxNorm normalized name: reteplase
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose reteplase
Trial: 17954798
Drug: Standard-dose abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose abciximab plus half-dose reteplase
Trial: 10440620
Drug: Sparfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (400 mg loading dose, followed by 200 mg once daily for 10 days)
Trial: 7784810
Drug: Tetracycline 250
RxNorm normalized name: tetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 250 mg (TTC)
Trial: 1982108
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine BID
Trial: 538813
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of long-acting chloramphenicol (Tifomycine)
Trial: 24188161
Drug: Milnacipran (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (200 mg/day)
Trial: 24077206
Drug: Milnacipran (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (any dose)
Trial: 12122526
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no dopexamine infusion)
Trial: 7570898
Drug: Screening and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening and treatment programme for imported intestinal parasites
Trial: 428086
Drug: Chlorthalidone 50
RxNorm normalized name: chlorthalidone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 50 mg q.a.m.
Trial: 20524934
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and telmisartan (ARB) for 12 months
Trial: 20524934
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and enalapril (ACEI) for 12 months
Trial: 22037407
Drug: quetiapine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quetiapine (400 mg/day)
Trial: 16198059
Drug: fluphenazine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluphenazine (12.5 mg/day)
Trial: 12691536
Drug: ISIS 2302
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 2302 (antisense phosphorothioate oligonucleotide) at a fixed dose regimen of 250-400 mg, given three times weekly
Trial: 10496186
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant IFN beta‐1a (Rebif, Ares‐Serono) 22 microg once a week (QW)
Trial: 10496186
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant IFN beta‐1a (Rebif, Ares‐Serono) 22 microg three times a week
Trial: 10496186
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant IFN beta‐1a (Rebif, Ares‐Serono) 66 microg once a week (QW)
Trial: 2269924
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of silver sulfadiazine and hydrocortisone cream
Trial: 23282124
Drug: Valsartan (80‐320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (80‐320 mg) with bedtime dosing
Trial: 23282124
Drug: Valsartan (80‐320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (80‐320 mg) with awakening dosing
Trial: 20638877
Drug: S(+)‐ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine infusion (100‐h, starting at 5 mg/h to 20 mg/h)
Trial: 16716315
Drug: Laparoscopic unilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic unilateral tubal fulguration (treatment group, 7 patients)
Trial: 15633319
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (GTRC and EMDC)
Trial: 7971000
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil (10 mg/kg/day, once daily for 10 days)
Trial: 7971000
Drug: Cefixime (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (8 mg/kg/day, once daily for 10 days)
Trial: 2446077
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg orally once or twice daily for 4 weeks)
Trial: 18973991
Drug: Aripiprazole (15-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (15-30 mg/day)
Trial: 16199834
Drug: Olanzapine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10-20 mg/day)
Trial: 15623462
Drug: DIM (108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIM (108 mg/day) for 30 days
Trial: 22187126
Drug: Concurrent epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent epirubicin 83 mg/m(2) and paclitaxel 187 mg/m(2)
Trial: 15691532
Drug: CBT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT plus Fluoxetine (60 mg/day)
Trial: 24256157
Drug: Flexibly timed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexibly timed discontinuation of supervision
Trial: 23582628
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 to 10 mg/day
Trial: 18984840
Drug: Riboflavin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin (200 mg daily)
Trial: 16616233
Drug: Valsartan (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (160 mg daily for 12 weeks)
Trial: 10971235
Drug: 1 L
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L of cafetière (French press) coffee daily
Trial: 8971064
Drug: Selenium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium treatment (200 microg per day)
Trial: 15353873
Drug: Enalapril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10-20 mg daily)
Trial: 28176599
Drug: Combined (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined (oral + topical) tranexamic acid (TXA)
Trial: 27527817
Drug: Fast injection
RxNorm normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fast injection (2‐4mL/s)
Trial: 27527817
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection (5‐10mL/s)
Trial: 27527817
Drug: Fast injection
RxNorm normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fast injection
Trial: 27527817
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection
Trial: 25105547
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise program (SEP) plus at home nonsupervised exercise therapy (non‐SET)
Trial: 21691756
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication
Trial: 2162281
Drug: Inspiratory flow
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory flow rate of 50 l/min
Trial: 2162281
Drug: Inspiratory flow
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory flow rate of 150 l/min
Trial: 27379388
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h infusion)
Trial: 17083585
Drug: Poly-L-lactic acid
RxNorm normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly-L-lactic acid (PLLA) injections
Trial: 11423702
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of 68 g olive and 12 g sunflower oil/day (MO; total 80 g)
Trial: 11423702
Drug: 80 g
RxNorm normalized name: PEG-80 GLYCERYL COCOATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g corn oil (CO)/day
Trial: 3333523
Drug: Propranolol 160
RxNorm normalized name: propranolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 160 mg slow release once daily
Trial: 2943760
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% clindamycin phosphate applied twice daily for 8 weeks
Trial: 23731195
Drug: Vehicle applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vehicle applied twice daily for 8 weeks
Trial: 17595452
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (2800 mg daily for 7 days)
Trial: 10099043
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate 50 mg intramuscularly weekly and 1,000 mg oral calcium carbonate daily (NDC group)
Trial: 10099043
Drug: Calcium alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium alone 1,000 mg oral calcium carbonate daily (CAL group)
Trial: 7656846
Drug: Intracoronary bisoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary bisoprolol (0.01 mg/kg body weight)
Trial: 7656846
Drug: Intravenous bisoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bisoprolol (2.5 mg)
Trial: 237849
Drug: Bromazepam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam (5 mg t.d.s. for 3 weeks)
Trial: 237849
Drug: Diazepam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5 mg t.d.s. for 3 weeks)
Trial: 16982107
Drug: Metformin (Met)
RxNorm normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (Met)
Trial: 25402241
Drug: Low risk
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low risk with varnish (oral health education every three months + varnish biannually)
Trial: 25402241
Drug: High risk
RxNorm normalized name: Hep B, adolescent/high risk infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High risk with sealant (oral health education every three months + a single application of sealant)
Trial: 25402241
Drug: Low risk
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low risk with sealant (oral health education every three months + a single application of sealant)
Trial: 9155961
Drug: Fluconazole 150
RxNorm normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 150 mg once weekly for 4-6 weeks
Trial: 9155961
Drug: Griseofulvin 500
RxNorm normalized name: griseofulvin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin 500 mg once daily for 4-6 weeks
Trial: 7952982
Drug: Imipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (mean 233 mg/day)
Trial: 29198188
Drug: 800 g
RxNorm normalized name: LEVETIRACETAM 19800 g in 20000 g NOT APPLICABLE POWDER [X]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 g milk
Trial: 29198188
Drug: 800 g
RxNorm normalized name: LEVETIRACETAM 19800 g in 20000 g NOT APPLICABLE POWDER [X]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 g yogurt
Trial: 23683794
Drug: Illicit use
RxNorm normalized name: Illicium difengpi bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Illicit use of prescription stimulants (IUPS)
Trial: 11157651
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (INR 2.0 to 3.0)
Trial: 24316430
Drug: Glycosylated 1,25(OH)2D3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycosylated 1,25(OH)2D3, single oral dose, up to 40-fold the recommended daily dose (0.5μg/subject/day)
Trial: 10453590
Drug: Tang Shen
RxNorm normalized name: Ren shen
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tang Shen Ning (TSN) + western medicine
Trial: 7881702
Drug: Calcium-heparin (12,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-heparin (12,500 IU once daily)
Trial: 7881702
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) (300 mg twice daily)
Trial: 3108922
Drug: 1.5‐5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5‐5 mg haloperidol orally and/or intravenously
Trial: 31926142
Drug: Virtual Reality-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality-Based Therapy (VRBT)
Trial: 30656509
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) 0.2 mg/mL for 2 min before surgery
Trial: 30656509
Drug: Bevacizumab-methylcellulose mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab-methylcellulose mixture (BMM) 1.25 mg in 2% methylcellulose injected subconjunctivally after surgery
Trial: 25376972
Drug: Adductor Canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor Canal Block (ACB) with ropivacaine 0.2% 30 mL
Trial: 25376972
Drug: Femoral Nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral Nerve Block (FNB) with ropivacaine 0.2% 30 mL
Trial: 23657413
Drug: Corega Brite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corega Brite combined with Oral Balance (artificial saliva)
Trial: 17106661
Drug: Short wave
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short wave therapy for 3 weeks
Trial: 17106661
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (routine ambulatory care)
Trial: 14633141
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1 g twice daily 24 hours before and after angiography
Trial: 30637727
Drug: Emollient cream
RxNorm normalized name: EMOLLIENT CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient cream treatment on upper back
Trial: 30341986
Drug: Four serial
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four serial phlebotomy procedures followed by intravenous infusion of placebo normal saline
Trial: 24279907
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline spray)
Trial: 22796139
Drug: VAX128A (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAX128A (up to 8 μg)
Trial: 22796139
Drug: VAX128B (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAX128B (up to 16 μg)
Trial: 22796139
Drug: VAX128C (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAX128C (up to 20 μg)
Trial: 20430328
Drug: Low-dose BoNT‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose BoNT‐A (100 units)
Trial: 20430328
Drug: High-dose BoNT‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose BoNT‐A (200 units)
Trial: 18492675
Drug: Sock with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sock with nanocapsules containing a hydrating agent
Trial: 15968657
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of carbogen
Trial: 15968657
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of oxygen
Trial: 10916802
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitors (AECI)
Trial: 1562290
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone triiodothyronine (T3) 30 micrograms/day
Trial: 3910057
Drug: Cimetidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (600 mg bid)
Trial: 3554990
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg bid)
Trial: 29979837
Drug: Inhaled anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled anesthesia (IA)
Trial: 11676576
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (TG)
Trial: 9158048
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg of praziquantel in two divided doses administered 6 hr apart at Farshout
Trial: 9158048
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg of praziquantel in a single dose at Om El‐Laban
Trial: 7954027
Drug: Dichloroacetate (DCA)
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloroacetate (DCA) 50 mg/kg intravenously
Trial: 2164655
Drug: IVIG, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG, 500 mg/kg
Trial: 2164655
Drug: 5% albumin-normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% albumin-normal saline (placebo), 10 ml/kg
Trial: 30795705
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (FF/VI) 100/25 µg once daily (OD)
Trial: 28088032
Drug: Oral cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabidiol (200mg)
Trial: 28088032
Drug: Oral cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabidiol (400mg)
Trial: 3121718
Drug: Phenelzine, L-tryptophan,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenelzine, L-tryptophan, and lithium ('5HT-cocktail')
Trial: 20522984
Drug: Morning administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administration of rosuvastatin
Trial: 20522984
Drug: Evening administration
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening administration of rosuvastatin
Trial: 18185500
Drug: 0, 2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0, 2.5, and 5 mg intravenous Delta‐9‐THC
Trial: 3655000
Drug: 3-g q4h
RxNorm normalized name: glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-g q4h regimen of azlocillin
Trial: 3655000
Drug: 5-g q8h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-g q8h regimen of azlocillin
Trial: 25690082
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation powder (TIP)
Trial: 26203099
Drug: 5.0 g
RxNorm normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 g agave inulin/d
Trial: 26203099
Drug: 7.5 g
RxNorm normalized name: glucose 15 GM per 37.5 GM Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 g agave inulin/d
Trial: 26203099
Drug: Agave inulin
RxNorm normalized name: Agave Inulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agave inulin (5.0 g and 7.5 g)
Trial: 6141424
Drug: Intermediate-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose methotrexate (1000 mg/m2) in addition to conventional oral therapy of mercaptopurine and low-dose methotrexate
Trial: 27743432
Drug: Multispecies probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multispecies probiotic supplements (2 × 10^9 CFU/g each of Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum)
Trial: 24865677
Drug: TDEN vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDEN vaccine
Trial: 10223782
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg policosanol once a day for the next 12 weeks
Trial: 1975150
Drug: Vecuronium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.1 mg/kg)
Trial: 6128860
Drug: Vecuronium (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.025 mg/kg maintenance doses)
Trial: 26467311
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D plus calcium supplementation (50,000 IU vitamin D3 every 2 weeks plus 1000 mg day(-1) calcium)
Trial: 16046582
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/d) for 28 days
Trial: 10423764
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg orally 45 min before MIBI injection